No Data
No Data
Yiming Angko-B (01541): The China Securities Regulatory Commission issued a notice of record regarding the full circulation of certain H shares of the company's unlisted shares
According to the Zhitong Finance App, Yiming Angko-B (01541) issued an announcement. The company has recently received a filing notice from the China Securities Regulatory Commission to implement the full circulation of the company's H shares. According to the filing notice, the company has completed the implementation filing with the China Securities Regulatory Commission on the conversion of up to 120 million unlisted shares of the company to H shares of the company. The filing notice is valid for 12 months from May 14, 2024. The company will apply to the Stock Exchange for approval to list and trade the relevant H shares on the main board of the Stock Exchange. As of the date of this announcement, the details of the implementation plan for conversion and listing have not been finalized.
Yiming Angko-B (01541.HK) appoints Guan Mei as Executive Director
Gelonghui, May 28 | Yiming Angko-B (01541.HK) announced that after shareholders' approval at the annual shareholders' meeting, Ms. Guan Mei was appointed as the executive director of the first board of directors. Ms. Kwan's term of office will begin on May 28, 2024 and end when the first term of the board expires.
Immuneonco Biopharmaceuticals Gets Regulatory Go-Ahead for Phase 3 Trial of Myelodysplastic Syndrome Drug in China
Immuneonco Biopharmaceuticals (HKG:1541) has obtained approval from the National Medical Products Administration of China to conduct a phase III clinical trial of IMM01 (Timdarpacept) in combination w
Yiming Angko-B (01541.HK): IMM01 (tidapecip) combined with azacitidine was approved by the State Drug Administration to conduct a randomized, double-blind, controlled phase III clinical trial plan
Gelonghui, May 17 | Yiming Angko-B (01541.HK) issued an announcement. The Group was approved by the Drug Evaluation Center of the State Drug Administration (“Drug Evaluation Center”) to conduct a randomized, double-blind, controlled IMM01 (tidapecip) combined with azacitidine phase III clinical trial plan for first-line treatment of high-risk myelodysplastic syndrome (HRMDS). Furthermore, the latest results of the IMM01 (tidapecip) combined with azacitidine phase II clinical trial program have been accepted by the 2024 American Society of Clinical Oncology (“ASC”) to be held in Chicago on June 1, 2024
宜明昂科-B:2023年報
Gelonghui Announcements Selected (Hong Kong Stock) | Xiaopeng Automobile-W (09868.HK) signs strategic cooperation framework agreement with Volkswagen Group on electronic and electrical architecture technology
[Today's Focus] Xiaopeng Motor-W (09868.HK) and Volkswagen Group sign a strategic cooperation framework agreement on electronic and electrical architecture technology Xiaopeng Motor-W (09868.HK) and Volkswagen Group jointly announced that Xiaopeng Motor and Volkswagen Group have signed a strategic cooperation framework agreement on electronic and electrical architecture (“electronic and electrical architecture”) technology. The industry-leading electronic and electrical architecture independently developed by Xiaopeng Motor is the core technology of its vertically integrated software and hardware technology. Thanks to this advanced electronic and electrical architecture, software such as intelligent driving assistance software and connected vehicle operating systems can be decoupled from the underlying hardware and vehicle platform,
No Data